Skip to main content

Table 4 Description of urticaria activity score, weekly itch severity score, and the magnitude of change before and after treatment

From: Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review

Study ID Sample size Intervention UAS7 baseline (mean ± SD) Change in UAS7 (mean ± SD) UAS < 6 n (%) ISS baseline (mean ± SD) Change in weekly ISS (mean ± SD
1 27 Omalizumab 75-375 mg 24.6 ± 7.4 −17.8Ϯ - - -
22 Placebo 21.3 ± 7.6 −7.9 - - -
2 23 Omalizumab 75 mg 27.3 ± 8.31 −9.8 ± 11.75 - 13.1 ± 3.53 −4.5 ± 5.84
25 Omalizumab 300 mg 27.3 ± 7.19 −19.9 ± 12.38Ϯ - 13 ± 3.72 −9.2 ± 5.98Ϯ
21 Omalizumab 600 mg 26.8 ± 6.98 −14.6 ± 10.17 - 12.6 ± 3.19 −6.5 ± 5.63
21 Placebo 31 ± 7.32 −69 ± 9.84 - 14 ± 4.23 -3.5±5.22
3 82 75 mg omalizumab 30.7 ± 6.9 - 22 (27) 14 ± 3.7 -5.9±6.5
83 150 mg omalizumab 31.4 ± 7.0 - 35 (43)Ϯ 14.2 ± 4.1 -8.1±6.4Ϯ
79 300 mg omalizumab 29.5 ± 6.9 - 52 (66)Ϯ 13.7 ± 3.5 -9.8±6.0Ϯ
79 Placebo 31 ± 6.6 - 15 (19) 14 ± 3.4 -5.1±5.6
4 252 Omalizumab 300 mg 31.2 ± 6.6 −19 (20.6 a-17.4)*Ϯ 132 (52)Ϯ 14 ± 3.6 -8.6 (-9.3 a -7.8)*Ϯ
84 Placebo 30.2 ± 6.7 −8.5(−11.1 a-5.9)*Ϯ 10 (12) 13.8 ± 3.6 -4.0 (-5.3 a -2.7)*
5 78 Omalizumab 75 mg 31.7 ± 6.7 −13.82 ± 13.26Ϯ 20 (26) 14.5 ± 3.6 -6.46±6.14Ϯ
80 Omalizumab 150 mg 30.3 ± 7.3 −14.44 ± 12.95Ϯ 32 (40) 14.1 ± 3.8 -6.66±6.28Ϯ
81 Omalizumab 300 mg 31.3 ± 5.8 −20.75 ± 12.17Ϯ 42 (52) 14.2 ± 3.3 -9.4±5.73Ϯ
80 Placebo 31.1 ± 6.7 −8.01 ± 11.47 9 (11) 14.4 ± 3.5 -3.63±5.22
  1. UAS7: Urticaria Activity Index in 7 days, ISS: Itch Severity Score, SD: standard deviation, *mean and 95% confidence interval, Ϯ p<0.01 compared to placebo.